Drugs / TRC102
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00692159 | Jun 2008 → Jun 2010 | neoplasm | Tracon Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01851369 | Jul 2013 → Aug 2023 | lymphoma, maligant granulosa cell tumor of ovary, metastasis from malignant tumor of colon, non-small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRC102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00692159 ↗ |
| Action | Inhibit | “TRC102 (methoxyamine hydrochloride (HCl) acts through a novel mechanism to inhibit BER” NCT01851369 ↗ |
| Route | Oral | “Oral TRC102 solution” NCT00692159 ↗ |